Blood-Based Proteomic Test for NSCLC Will Be Reimbursed by UnitedHealthcare

The diagnostic test, developed by Biodesix, Inc, will help guide treatment decisions in patients with advanced lung cancer.

Biodesix, Inc, today announced that its VeriStrat test received a positive coverage decision from UnitedHealthcare, one of the largest commercial insurance companies in the US, with a published 44.7 million covered lives. In its Medical Policy, UnitedHealthcare describes VeriStrat as “…proven for guiding treatment decisions in patients with advanced non-small cell lung cancer (NSCLC).”

VeriStrat, included in the standard of care guidelines, is a blood-based proteomic test that provides physicians with prognostic and predictive information that helps guide treatment of advanced NSCLC. Patients with a VeriStrat Poor test result have a shorter median overall survival than those with a VeriStrat Good result. Understanding the patient’s disease state can help inform physicians’ decisions on chemotherapy, palliative care or clinical trials.

Read the complete news release on Yahoo!:

Related Videos
dr mohamad mohty
dr ryan jacobs
Video 2 - 3 KOLs are featured in, "Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis"
Video 1 - 3 KOLs are featured in, "Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression"
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Cente
A panel of experts on Alzheimer's disease
Related Content
CH LogoCenter for Biosimilars Logo